Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,753 active trials43 approved drugs423 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,705 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,321)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07104266 | Triple Negative Breast Cancer and Celecoxib. Pilot Study | recruiting | Phase 2 | 30 | Université de SherbrookeOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT05953961 | 90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia(REALM) | recruiting | N/A | 50 | Ochsner Health SystemOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07100288 | Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer(INFPELV) | recruiting | — | 200 | Complejo Hospitalario Universitario Insular Materno InfantilOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07101237 | An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer. | recruiting | — | 308 | Peking Union Medical College HospitalOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06069297 | Prehabilitation in Pancreatic Surgery(PIPS) | recruiting | N/A | 238 | IRCCS San RaffaeleOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06358625 | Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer(CRANIUM) | recruiting | — | 120 | Center Eugene MarquisOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06595160 | Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy | recruiting | — | 87 | Emory UniversityOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06841172 | Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC | recruiting | Phase 3 | 132 | Shandong Cancer Hospital and InstituteOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07097935 | Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 104 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06695026 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 45 | Rznomics, Inc.OTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07080021 | A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer(MRD) | recruiting | — | 119 | Ruijin HospitalOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07091942 | Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma | recruiting | — | 1,600 | National Taiwan University HospitalOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05574647 | Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for Cancer(IP7-PACIFIC) | recruiting | N/A | 3,600 | Imperial College LondonOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT06819566 | Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC(ESCOAT) | recruiting | Phase 2 | 44 | Asan Medical CenterOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT06031285 | Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial | recruiting | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07059936 | Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver) | recruiting | — | 350 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07077356 | Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma | recruiting | Phase 1 | 15 | West China HospitalOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07077876 | Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment(CHOICE) | recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT06642220 | Ablative Radioembolization of Renal Cell Carcinoma Trial(ARRCC) | recruiting | Phase 2 | 16 | Derek W. CoolOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07073755 | Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd | recruiting | — | 200 | Hunan Cancer HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT06329973 | Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer | recruiting | Phase 1 / Phase 2 | 70 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05810402 | Liver Cancer and Immunotherapy in the Liquid Biopsy Era(LILIPSY) | recruiting | N/A | 60 | University Hospital, MontpellierOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT06287749 | French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC) | recruiting | — | 37 | University Hospital, MontpellierOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT05722795 | Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)(I-CONIC) | recruiting | N/A | 40 | Vastra Gotaland RegionOTHER_GOV | 1 | Jul 9, 2025 | clinicaltrials |
| NCT05797805 | A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 178 | Iterion TherapeuticsINDUSTRY | 2 | Jul 4, 2025 | clinicaltrials |
| NCT06903312 | Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.(ITALIC-RCC) | recruiting | Phase 4 | 409 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT07047586 | Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab(LEAF-01) | recruiting | Phase 2 | 146 | Fudan UniversityOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06954467 | JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 72 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06999174 | Multiparametric MRI for Characterization of Hepatocellular Carcinoma | recruiting | — | 128 | University Hospital MuensterOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07047495 | Personalization of External Beam Radiation Therapy in Localised Tumours(MINIONS) | recruiting | — | 35 | European Institute of OncologyOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT05796973 | Measuring Oncological Value of Exercise and Statin(MOVES) | recruiting | Phase 3 | 240 | Tampere University HospitalOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT05451043 | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | recruiting | Phase 2 | 62 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06769425 | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors(HS-10502) | recruiting | Phase 1 | 157 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07034742 | Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer | recruiting | Early Phase 1 | 136 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06379698 | Rein 3D PRINT PERSONALIZE(R3DP-P) | recruiting | N/A | 39 | University Hospital, BordeauxOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07018518 | PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma | recruiting | Phase 1 | 25 | Chinese PLA General HospitalOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07030569 | RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study(RADIOSPHER2) | recruiting | — | 500 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07020169 | Using 3D Kidney Model Based on Artificial Intelligence to Assist Partial Nephrectomy: A Prospective Validation Study | recruiting | N/A | 232 | Shao PengfeiOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04348838 | Prospective Cohort of Patients With Hepatocellular Carcinoma in France(CHIEF) | recruiting | — | 5,000 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07010198 | Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City | recruiting | — | 4,500 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT05326620 | National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)(PRO-RCC) | recruiting | — | 2,000 | PROspective Renal Cancer Cohort FoundationOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06596915 | Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 167 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05513365 | Phase II Dutasteride in Combination With CAB vs CAB in SDC(DUCT) | recruiting | Phase 2 | 26 | Radboud University Medical CenterOTHER | 1 | Jun 4, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Aug 5, 2025source: clinicaltrials